Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$131K Buy
5,442
+4,128
+314% +$108K 0.04% 131
2026
Q1
$36.9K Hold
1,314
0.01% 182
2025
Q4
$32.7K Sell
1,314
-370
-22% -$9.33K 0.01% 181
2025
Q3
$42.9K Sell
1,684
-1,989
-54% -$49.1K 0.01% 173
2025
Q2
$89K Buy
3,673
+49
+1% +$1.14K 0.03% 138
2025
Q1
$91.8K Buy
3,624
+2,280
+170% +$59.7K 0.03% 130
2024
Q4
$35.7K Buy
+1,344
New +$36.5K 0.01% 163
2020
Q3
Sell
-7,064
Closed -$219K 127
2020
Q2
$219K Buy
+7,064
New +$240K 0.05% 106
2019
Q1
Sell
-523
Closed -$22K 92
2018
Q4
$22K Buy
+523
New +$21.7K 0.01% 86
2013
Q4
Sell
-7,850
Closed -$214K 124
2013
Q3
$214K Sell
7,850
-422
-5% -$11.5K 0.03% 108
2013
Q2
$220K Buy
+8,272
New +$229K 0.04% 99

Other funds holding PFE

S&T Bank's PFE Position: Q2 2026 in Review

S&T Bank increased its Pfizer (PFE) stake by 314% in Q2 2026, buying an estimated $108K and bringing the position to 5,442 shares worth $131K. The position accounts for 0.04% of the portfolio, ranked #131.

S&T Bank first reported a position in PFE in Q2 2013 and has held it in 11 quarters since. The position peaked at $220K in Q2 2013. 2,818 funds tracked by Wall St. Rank hold PFE as of Q2 2026.

  • S&T Bank held 5,442 shares of Pfizer worth $131K as of Q2 2026.
  • S&T Bank bought 4,128 Pfizer shares in Q2 2026, an estimated $108K.
  • Pfizer made up 0.04% of S&T Bank's portfolio in Q2 2026, its #131 holding.
  • S&T Bank first reported a position in Pfizer in Q2 2013 and has held it in 11 quarters since.
  • S&T Bank's Pfizer position peaked at $220K in Q2 2013.
  • 2,818 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.

Based on S&T Bank's 13F filing for Q2 2026, filed 12 Aug 2026.